-
A booster dose of J&J vaccine gave comparable protection to other vaccines, the company said.
-
The second shot was found to give 100% against severe disease, it said, citing a study.
-
The second shot was also 94% protective against symptomatic infection.
-
See more stories on Insider’s business page.
Two doses of the Johnson & Johnson COVID-19 vaccine provided an efficacy similar to that of the Moderna and Pfizer vaccines, the company said Tuesday.
The company said in a press release, citing its own studies, that the booster provided:
-
94% protection against symptomatic infection,
-
100% protection against severe disease at least 14 days after the second shot.
The second dose was administered 2 months after the first dose, the company said.
The figures are based on a 30,000-patient study, called ENSEMBLE 2, in which a second dose was given to volunteers 56 days apart, STAT News reported.
Of those, 14 cases of moderate-to-severe Covid had gotten two doses, compared to 52 among those given placebo doses. Zero were severely or critically ill, the company said in a press release.
The data has not been peer-reviewed or published in a peer-reviewed journal, The Wall Street Journal noted.
The shot was first presented as a single-dose vaccine, unlike the two-shot regimes for Pfizer and Moderna.
But a clinical study revealed that a single J&J dose was less effective than the other approved vaccines.
The study put the vaccine’s efficacy at 66% at preventing symptomatic disease. By comparison, clinical trials put the the two-dose Moderna and Pfizer efficacy against symptomatic disease at risk 94 and 95%, respectively, although it is difficult to compare trials with different protocols head to head.
A recent CDC study confirmed the gap in efficacy between the shots. The study found that the single-shot J&J vaccine still greatly reduced the risk of hospitalization from COVID-19 – by 71%.
But the two-dose Moderna and Pfizer further reduced the risk, by 93% and 88%, respectively.
US officials have approved only the single-dose approach for the J&J vaccine, and would need to take further steps to authorize second doses.
Read the original article on Business Insider